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New progresses into the molecular and cellular mechanisms of autism spectrum disor-
ders (ASDs) have been discussed in 1 day international symposium held in Pavia (Italy) on
July 4th, 2014 entitled “synapses as therapeutic targets for autism spectrum disorders”
(satellite of the FENS Forum for Neuroscience, Milan, 2014). In particular, world experts in
the field have highlighted how animal models of ASDs have greatly advanced our under-
standing of the molecular pathways involved in synaptic dysfunction leading sometimes
to “synaptic clinical trials” in children.
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Autism comprises a wide range of neuro-developmental disor-
ders known as autism spectrum disorders (ASDs), characterized
by deficits in verbal and non-verbal communication, impaired
social interactions, restricted interest, and stereotyped behavior.
ASDs affect 1 over 150/200 children, with onset before 3 years
of age. The higher incidence of these disorders in recent years
can be attributed to the improvement of the diagnostic criteria
in general and to the increased attention of the medical com-
munity (Geschwind and Levitt, 2007). Unlike idiopathic forms,
syndromic forms constitute only 10% of cases often associ-
ated with malformations and/or dysmorphic features. Syndromic
forms originate from well-known genetic or genomic disorders
(Lintas and Persico, 2009). These include fragile X, Angelman,
Rett syndromes, neurofibromatosis, tuberous sclerosis, etc. (Ben-
venuto et al., 2009). Interestingly, evidence has been provided that,
in a small number of cases, single mutations in genes encoding
for synaptic proteins account for behavioral deficits observed in
autistic children. Although rare, these new discoveries point to
synapses as possible sites of autism’s origin (Südhof, 2008). In
particular, the neurotransmitter GABA has emerged as one of
the major players in the assembly and formation of neuronal cir-
cuits early in development (Ben-Ari et al., 2012), and deficits in
GABAergic signaling are instrumental in the genesis of ASD as
demonstrated by the high co-morbidity of these disorders with
epilepsy.
In order to identify the molecular and cellular mechanisms
underlying ASDs, several animal models have been generated over
the last decade. To this aim, genetic defects detected in patients
have been introduced in the mouse genome. Animal studies have
revealed important dysfunctions in synaptic signaling associated
with behavioral deficits reminiscent of those found in autistic
children. This has allowed to develop new tools for the treat-
ment of ASDs opening new perspectives for early therapeutic
interventions.
To highlight recent progress in these specific points, leading
experts in the field gathered together in Pavia on July 4th 2014 for
1 day symposium (satellite of the FENS Forum) entitled “synapses
as therapeutic targets for autism spectrum disorders.” We dis-
cussed how animal models greatly advanced our understanding
of the molecular pathways involved in synaptic dysfunction in
ASDs leading sometimes to “synaptic clinical trials” in children.
Christian Rosenmund (Berlin, Germany) talked about current
work obtained in his laboratory on the cellular mechanisms under-
lying the Rett syndrome (RTT), a postnatal neurological disorder
affecting 1/10000 girls. RTT is caused by loss of function muta-
tions in the X-linked gene encoding the transcriptional repressor,
methyl-CpG binding protein 2 (MECP2). Rett patients exhibit
impaired motor coordination, learning deficits, irregular breath-
ing, and seizures. Recent findings show that over-expression of
wild-type (WT) MeCP2, due to gene duplications, causes also
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mental retardation and progressive neurological symptoms in
males. Neurological phenotypes involve an imbalance of exci-
tation and inhibition in neural circuits caused by too little or
too much MeCP2 activity. Using a reduced experimental system
consisting in growing single neurons on micro-island cultures,
he provided evidence for specific determination of cell intrin-
sic mechanisms of MeCP2 regulation (Chao et al., 2007, 2010).
The cellular expression levels of MeCP2 directly regulate synapse
formation in cultured cortical excitatory neurons, and the under-
lying mechanism seems to be related to impaired autocrine BDNF
function. These results form the basis of future studies to develop
putative rectifying treatments to regain balance of excitation and
inhibition in RETT patients.
Maria Vincenza Catania (Catania, Italy) briefly synthesized the
state of the art research supporting the notion that dysfunctions
of group-I metabotropic glutamate receptor 5 (mGlu5) are impli-
cated in the pathophysiology of fragile X syndrome (FXS), the
most common form of inherited intellectual disability and an
important monogenic cause of autism. In most cases, FXS is
caused by mutations in the fragile X mental retardation gene 1
(FMR1), silencing of the gene and ensuing lack of the encoded
fragile X mental retardation protein (FMRP), an RNA binding
protein involved in RNA metabolism and protein synthesis. FMRP
is present at synapses and controls local mRNA translation upon
synaptic activity. Although much work has focused on dysregu-
lation of mGlu5 signaling to synaptic protein synthesis, emerg-
ing evidence finds abnormal mGlu5 receptor interactions with
its scaffolding Homer protein, which results in mGlu5 receptor
dysfunction and phenotypes independent of signaling to pro-
tein synthesis (D’Antoni et al., 2014). In particular, in the brain
of Fmr1 knock-out mice, mGlu5 receptors are less associated to
the constitutive forms of Homer proteins (Giuffrida et al., 2005;
Ronesi et al., 2012). In the absence of FMRP, several properties and
functions of mGlu5 receptors are altered, partly as a consequence
of mGlu5/Homer disruption. She discussed the implication of
these findings for the pathophysiology and therapeutic correction
of FXS.
Paolo Curatolo (Rome, Italy) described recent data on tuber-
ous sclerosis complex (TSC), caused by haploinsufficiency of
the TSC1 and TSC2 genes. This leads to over-activation of the
mTORC1-eIF4E pathway, known to regulate growth and synaptic
plasticity of glutamatergic neurons with alterations of synaptic
homeostasis. Although the exact mechanisms of ASDs in TSC
are still unclear, changes in the expression of specific AMPA and
GABAA receptor subunits, as well as loss of GABAergic interneu-
rons have been described (Curatolo et al., 2010). Interestingly,
mouse models of TSC have demonstrated that the behavioral
phenotype may be the direct consequence of the TSC1/TSC2
dysfunction. Pharmacological inhibition of the mTOR pathway
with rapamycin is able to restore the excitatory/inhibitory bal-
ance and to reverse the autistic-like behavior of TSC2(+/−) mice
(Sato et al., 2012). Furthermore, both heterozygous and homozy-
gous loss of TSC1 in mouse cerebellar Purkinje cells (PC) results in
autistic-like behavior associated with a decreased in PC excitability.
These effects can be prevented by rapamycin, suggesting a possi-
ble therapeutic role for mTOR inhibition in TSC-related ASDs
(Tsai et al., 2012). As a whole, these findings suggest that mTOR
over-activation contributes to behavioral phenotypes of TSC-
related autism and mTOR inhibitors offer potential therapeutic
avenues for the pharmacological treatment of ASD-associated with
mTORpathies.
Lisa Mapelli (from Egidio D’Angelo’s group, Pavia, Italy) dis-
cussed modifications of cerebellar circuits in an animal model
of the Phelan–McDermid syndrome. This autistic syndrome is
caused by a deletion of the terminal portion of chromosome 22
(22q13.3) that involves both Shank3 and Ib2 genes. The latter
encodes for the synaptic protein IB2 that takes part to the NMDA
receptor interactome. Electrophysiological recordings combined
with voltage-sensitive dye imaging in Ib2 KO mice (Giza et al.,
2010) unveiled a three to fivefold increase in NMDA receptor-
mediated currents in cerebellar granule cells associated with an
altered spatial distribution of excitation and inhibition in the
granular layer (Mapelli et al. unpublished data). The altered excita-
tory/inhibitory balance was accompanied by changes in amplitude
and spatial organization of long-term potentiation (LTP) and
long-term depression (LTD) at mossy fiber-granule cell synapses.
These changes, reminiscent of those reported in other animal
models of ASD (Casanova, 2006) suggest common alterations in
neuronal network activity in different brain areas.
Enrico Cherubini (Trieste, Italy) illustrated the neuroligin (NL)
model generated in Südhof ’s laboratory by introducing in mice a
single mutation (R451C) of the human Nlgn3 gene detected in a
family with children affected by ASDs (Tabuchi et al., 2007). NLs
are post-synaptic adhesion molecules that bind to their presy-
naptic partners neurexins to functionally couple the post-synaptic
densities with the transmitter release machinery. Mice carrying
the NL3R451C mutation show modifications of GABAergic sig-
naling associated with social deficits reminiscent of those found
in autistic children. A detailed analysis of GABAergic micro-
circuits in the hippocampus has unveiled an increased GABA
release from cholecystokinin-positive endocannabinoid-sensitive
interneurons and a decreased GABA release from parvalbumin-
positive (PV) basket cells (Földy et al., 2013). A reduced probability
of GABA release from PV-positive basket cells was detected also
in layer IV somatosensory cortex (Cellot and Cherubini, 2014).
Such deficit determines an alteration of the excitatory/inhibitory
balance and a modification of the temporal window for integrat-
ing sensory signals. This may alter coherent percepts in autistic
children.
Yuri Bozzi (Trento, Italy) reported a recent study on the
neurofibromin-extracellular-regulated kinase (ERK) cascade in
the hippocampus of WT and engrailed-2 knock-out (En2−/−)
mice before and after spatial learning. The homeobox-containing
transcription factor has been associated to ASD. En2−/−mice show
anatomical and behavioral “ASD-like” features, including loss of
forebrain interneurons (Sgadò et al., 2013a), reduced expression
of ASD-related genes (Sgadò et al., 2013b), decreased sociability,
and learning deficits (Brielmaier et al., 2012). Deficits in signaling
pathways involving neurofibromin and ERK have been associ-
ated to impaired learning. When compared to WT littermates,
En2−/− mice show impaired performance in the Morris water
maze (MWM), associated with a marked down-regulation of neu-
rofibromin expression in the hippocampus. ERK phosphorylation,
known to be induced in the presence of neurofibromin deficiency,
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is increased in the hippocampus of En2−/− mice after spatial
learning. Treatment of En2−/− mice with lovastatin, an indirect
inhibitor of ERK phosphorylation, markedly reduced ERK phos-
phorylation in the dentate gyrus, but was unable to rescue learning
deficits in MWM-trained mutant mice (Provenzano et al., 2014).
Further investigation is needed to unravel the complex molecular
mechanisms linking dysregulation of neurofibromin-dependent
pathways to spatial learning deficits in the En2 mouse model
of ASDs.
Yehezkel Ben-Ari (Marseille, France) discussed how under-
standing and treating neurological and psychiatric disorders is
conditioned by a better knowledge of developmental processes. In
the developing brain ionic currents, network activity, and mole-
cular processes have unique features and follow a developmental
sequence adapting them to their adult functions. Together with
Spitzer (Ben-Ari and Spitzer, 2010), he proposed the checkpoint
concept, according to which genes and neuronal activity cooper-
ate in series to control the adequacy of the program implemented.
In a previous study, the “neuroarcheology” theory was suggested
(Ben-Ari, 2008). This consisted in the hypothesis that genetic
or environmental insults may alter the developmental sequences
producing pre-symptomatic architectural or electric signatures of
disorders to come. In this perspective, neurons failing to imple-
ment their sequence, misplaced, or misconnected remain with
immature features that are the factor impacting the operation of
adjacent networks leading to the expression of neurological dis-
orders. These concepts have been confirmed in relation to many
early disorders (including infantile seizures, DCX mutations, TSC,
nodular heterotopia, etc.). This also implies that future treatments
will heavily rely on the use of selective drugs that antagonize
specifically immature currents in the adult brain. These issues
have been illustrated with recent clinical trials in autism success-
fully using the NKCC1 antagonist bumetanide (Lemonnier et al.,
2012). The validity of this approach has been confirmed in two
animal models of autism and fragile X where the diuretic amelio-
rated the behavioral and electrical features of autism (Tyzio et al.,
2014).
Lindsay M. Oberman (Providence, RI, USA) highlighted recent
studies showing the involvement of synaptic plasticity mechanisms
in the pathophysiology of ASDs (Oberman et al., 2013). While
most synaptic plasticity data in ASDs are derived from animal
models, direct measures of circuit level plasticity in humans can
be obtained by transcranial magnetic stimulation (TMS). This
consists in stimulating focally the cortex with small intracra-
nial electrical currents generated by a powerful and fluctuating
extracranial magnetic field. TMS provide the only non-invasive
method able to measure phenomena that closely resemble LTP
and LTD in humans. Recently, patterned bursting protocols (i.e.,
theta burst stimulation, TBS), mimicking paradigms used to assess
synaptic plasticity in acute rodent slices, have been developed.
When applied to the motor cortex, continuous (cTBS), or inter-
mittent TBS (iTBS) results in depression and potentiation of
cortical reactivity as indexed through suppression and facilitation
of motor evoked potentials (MEPs), respectively (Huang et al.,
2010). Furthermore, published data suggest that cTBS leads to
lasting suppression through enhancement of GABAergic inhibi-
tion (Benali et al., 2011). Both children and adults with ASDs
exhibit abnormal plasticity mechanism and GABAergic dysfunc-
tions (Oberman et al., 2010, 2012, 2013). Additional studies are
underway to clarify the relationship between these indices and
physiological and behavioral phenotype.
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